Welcome to our dedicated page for Sonoma Pharmaceuticals news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceuticals stock.
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is a leader in the healthcare industry, specializing in the development and production of stabilized hypochlorous acid (HOCl) products. Operating globally, the company delivers innovative solutions for wound care, animal health care, eye care, oral care, and dermatological conditions. With products such as Epicyn, Levicyn, Celacyn Gel, SebuDerm, and Ceramax, Sonoma addresses various health concerns including infections, itch, pain, scarring, and inflammation.
The company’s flagship Microcyn® technology is backed by in-vitro and clinical studies, showcasing its antimicrobial, antiviral, and anti-inflammatory properties. Recent achievements include the launch of LumacynTM Clarifying Mist for over-the-counter use in the U.S., and an agreement with NovaBay Pharmaceuticals for the sale of Avenova®-branded products in the EU.
Sonoma Pharmaceuticals has its headquarters in Boulder, Colorado, with additional manufacturing operations in Guadalajara, Mexico, and European marketing and sales offices in Roermond, Netherlands. The company's products are available in 55 countries, either directly or through partners, and it continues to seek new distribution opportunities.
Financially, Sonoma reported a 7% increase in quarterly revenues to $3.2 million for the period ending December 31, 2023. U.S. sales saw a 14% increase, supported by strong demand for consumer-focused animal health care and wound care products. The company’s strategic investments in R&D and expansion of distributor networks have started to yield results, reflected in improved margins and reduced operating expenses.
For more information, visit the official website at www.sonomapharma.com or contact their customer service at 720-452-9690 or customerservice@sonomapharma.com.
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced a 1-for-20 reverse split of its outstanding common stock, effective August 29, 2024, at 5:00 pm EDT. Trading on the adjusted basis will begin on August 30, 2024. This move aims to maintain the company's Nasdaq Capital Market listing by meeting the $1.00 minimum bid price requirement before September 16, 2024.
Key points:
- Common stock will reduce from ~20 million to ~1 million shares
- Authorized shares will increase from 24 million to 50 million
- No fractional shares will be issued; cash will be given in lieu
- Proportional adjustments to stock options and equity-compensation plans
- New CUSIP number will be issued
CEO Amy Trombly emphasized the importance of maintaining Nasdaq listing for business confidence and opportunities.
Sonoma Pharmaceuticals (Nasdaq: SNOA) and MicroSafe Group announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer. The product, manufactured by Sonoma using its patented Microcyn® technology, is now approved for use against Candida auris (C. auris) and Clostridium difficile (C. diff) with a 10-minute kill time.
Previously, Nanocyn® was approved with a 15-second kill time against SARS-CoV-2 and a 30-second kill time against Norovirus, Influenza A (H1N1), and bacteria like MRSA. The U.S. EPA has also approved Nanocyn® as an effective disinfectant against various pathogens. This extended approval highlights Nanocyn®'s broad-spectrum efficacy and its potential to enhance patient safety in healthcare settings.
Sonoma Pharmaceuticals (Nasdaq: SNOA) has announced a distribution agreement with a leading global healthcare distributor for its wound care products in the United States. The partnership will leverage the distributor's extensive network of hospital systems and healthcare channels to expand Sonoma's wound care business across the country.
Sonoma's products are based on their patented Microcyn® technology, which uses stabilized hypochlorous acid (HOCl) for various applications including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care. CEO Amy Trombly described the partnership as a "huge step forward" for the company's U.S. wound care business expansion.
Additional details about the agreement can be found in Sonoma's Current Report on Form 8-K filed with the SEC on August 21, 2024.
Sonoma Pharmaceuticals (NASDAQ: SNOA) reported financial results for Q1 FY2025 ended June 30, 2024. Key highlights include:
- European revenues increased 20% year-over-year
- Gross margin improved to 39% from 35% in the same period last year
- Net loss decreased by 19% compared to Q1 FY2024
- Total revenues remained flat at $3.4 million
- Operating expenses were nearly flat year-over-year at $2.5 million
- EBITDA loss remained stable at $1.0 million
- Cash and cash equivalents stood at $2.6 million as of June 30, 2024
The company expanded its product offerings and partnerships, including a new distribution agreement in Ukraine and increased presence in U.S. retail stores for its animal health care products.
Sonoma Pharmaceuticals (NASDAQ:SNOA) celebrates its 20th anniversary of selling wound care products in Europe. The company, known for its patented Microcyn® technology, announced a new partnership with Smart Healthcare Company (SHC) s.r.o. to distribute its Microdacyn60® wound care products in Ukraine. SHC, based in Slovakia, will collaborate with DANA MC, a major medical supplier in Ukraine. The Microdacyn60 solution and hydrogel, based on hypochlorous acid, aid in pain relief, irritation reduction, and wound healing by eliminating bacteria, fungi, and viruses without damaging healthy tissue. CEO Amy Trombly expressed pride in the milestone and the opportunity to address significant healthcare needs in Ukraine.
Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 14% increase in Q4 2024 revenues to $3.4 million, driven by rising product sales across all territories except 'Rest of the World'. Gross profit margin improved by 3% year-over-year to 32%. Despite a 24% rise in operating expenses due to increased R&D, net loss decreased by 18% to $1.1 million. For FY 2024, revenues dropped 4.5% to $12.7 million due to lower service revenue but gross profit margin increased to 37%. Net loss for the year improved by 6% to $4.8 million. CEO Amy Trombly highlighted product innovation and market expansion as key growth drivers.
Sonoma Pharmaceuticals, Inc. announced the availability of its MicrocynAH animal health care products in Menards home improvement stores. The products include a range of items for wound care, eye and ear care, and itch relief for various animals. The expansion aims to provide pet owners with safe and effective solutions for their pets' health needs.
FAQ
What is the current stock price of Sonoma Pharmaceuticals (SNOA)?
What is the market cap of Sonoma Pharmaceuticals (SNOA)?
What does Sonoma Pharmaceuticals specialize in?
What are some key products of Sonoma Pharmaceuticals?
Where is Sonoma Pharmaceuticals headquartered?
How did Sonoma Pharmaceuticals perform financially in the latest quarter?
What recent product launches has Sonoma Pharmaceuticals announced?
Who are some of Sonoma Pharmaceuticals' partners?
In how many countries are Sonoma Pharmaceuticals' products available?
What technology is central to Sonoma Pharmaceuticals' product line?
Where can consumers purchase Sonoma Pharmaceuticals' products?
How can I contact Sonoma Pharmaceuticals for partnership opportunities?
